On March 30, 2021 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that preclinical data of its TUSC2 immunogene therapy (REQORSA) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell lung cancer (NSCLC), will be featured in two presentations at the upcoming annual meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (AACR 21) taking place virtually from April 9-14, 2021 (Press release, Genprex, MAR 30, 2021, View Source [SID1234577371]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to the presentation of these data that highlight the potential of TUSC2 immunogene therapy to enhance chemo-immune combination treatments and overcome resistance to osimertinib in lung cancer, to an audience of the world’s leading cancer researchers," said Rodney Varner, President and Chief Executive Officer of Genprex. "As lung cancer is the leading cause of cancer deaths worldwide, we remain keenly focused on initiating our Acclaim-1 and Acclaim-2 clinical trials to evaluate REQORSA, our proprietary TUSC2 immunogene therapy, in non-small cell lung cancer."
Acclaim-1 is a Phase 1/2 combination clinical trial using REQORSA combined with AstraZeneca’s Tagrisso (osimertinib) in patients with late-stage NSCLC whose disease progressed after treatment with Tagrisso. Acclaim-2 is a Phase 1/2 combination clinical trial using REQORSA combined with Merck & Co’s Keytruda (pembrolizumab) in NSCLC patients who are low expressors of PD-L1.
Featured Genprex-supported abstracts to be presented at AACR (Free AACR Whitepaper) 21 include:
Oral Presentation
Session: MS.IM02.02 – Overcoming Resistance in the Tumor Microenvironment: Novel Immunomodulatory Agents
Title: "TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robus antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice"
Poster Number/Channel: #76/Channel 03
Presentation Date/Time: April 10, 2021 from 2:50-3:00 p.m. ET
Presenters: Ismail M. Meraz, Mourad Majidi, RuPing Shao, Feng Meng, Min Jin Ha, Elizabeth Shpall, Jack A. Roth. University of Texas MD Anderson Cancer Center, Houston, TX
Poster Presentation
Session: PO.ET03.01 – Drug Resistance in Molecular Targeted Therapies
Title: "Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC"
Poster Number: #1105
Presentation Date/Time: April 10, 2021 from 8:30 a.m. – 11:59 p.m. ET
Presenters: Ismail M. Meraz, Mourad Majidi, RuPing Shao, Lihui Gao, Meng Feng, Huiqin Chen, Min Jin Ha, Jack A. Roth. University of Texas MD Anderson Cancer Center, Houston, TX